Nonspecific histone deacetylase (HDAC) inhibition has been shown to facilitate the extinction of drug-seeking behavior in a manner resistant to reinstatement. A key open question is which specific HDAC is involved in the extinction of drug-seeking behavior. Using the selective HDAC3 inhibitor RGFP966, we investigated the role of HDAC3 in extinction and found that systemic treatment with RGFP966 facilitates extinction in mice in a manner resistant to reinstatement. We also investigated whether the facilitated extinction is related to the enhancement of extinction consolidation during extinction learning or to negative effects on performance or reconsolidation. These are key distinctions with regard to any compound being used to modulate extinction, because a more rapid decrease in a defined behavior is interpreted as facilitated extinction. Using an innovative combination of behavioral paradigms, we found that a single treatment of RGFP966 enhances extinction of a previously established cocaine-conditioned place preference, while simultaneously enhancing long-term object-location memory within subjects. During extinction consolidation, HDAC3 inhibition promotes a distinct pattern of histone acetylation linked to gene expression within the infralimbic cortex, hippocampus, and nucleus accumbens. Thus, the facilitated extinction of drug-seeking cannot be explained by adverse effects on performance. These results demonstrate that HDAC3 inhibition enhances the memory processes involved in extinction of drug-seeking behavior.

Results
RGFP966 in the Brain After Dosing. RGFP966 is an N-(o-aminophenyl)carboxamide HDAC inhibitor (Fig. S1A). As a class, these slow-on/slow-off, competitive tight-binding inhibitors target class I HDACs, with the greatest inhibition of HDAC3 (30–32). A substrate-dependent biochemical assay using recombinant human HDACs preincubated for 2 h with inhibitor (Reaction Biology) found that RGFP966 is specific for HDAC3, with an IC50 of...
showed enhanced preference for the object in a novel location after (posttraining) subthreshold OLM training (Fig. S2A). RGFP966 concentration remained high up to 60 min and then declined significantly by 120 min \([F(2,16) = 14.48, P < 0.001;\) Bonferroni post hoc: 30 min vs. 120 min, \(P < 0.05)\], but was still 0.57 \(\mu g/\mu l\) (1.5 \(\mu M\)). Distribution of RGFP966 to the CNS was relatively efficient, with a brain: plasma ratio of 0.45. These results confirm that s.c. dosing of RGFP966 at 10 mg/kg resulted in maximal brain exposure between 30 min and 1 h, with brain concentrations in excess of the IC50 of RGFP966 for HDAC3 for the entire sampling period (0.25–2 h).

**RGFP966 Treatment Enhances Long-Term Memory for Object Memory.**

To examine the ability of this HDAC3 inhibitor to modulate long-term memory consolidation, we treated mice with RGFP966 (3, 10, or 30 mg/kg) or vehicle and trained them in object recognition (ORM) or location-dependent object recognition (OLM), with a subthreshold training period. Systemic delivery of RGFP966 after ORM training (Fig. S2A) significantly increased preference for the novel object in a dose-dependent manner \([F(3,21) = 11.15, P < 0.01;\) Bonferroni post hoc vs. vehicle: 3 mg/kg RGFP966, \(P < 0.05;\) 10 mg/kg RGFP966, \(P < 0.05;\) 30 mg/kg RGFP966, \(P < 0.05)](Fig. S2B). Groups did not differ in terms of total exploration time of the two objects [vehicle: 3.8 ± 1.0, \(n = 6;\) RGFP966 3 mg/kg: 3.7 ± 0.4, \(n = 5;\) RGFP966 10 mg/kg: 4.5 ± 0.4, \(n = 9;\) RGFP966 30 mg/kg: 4.4 ± 0.7, \(n = 5;\) \(F(2,17) = 0.35, P = 0.79)](Fig. S2B). Mice treated with 10 mg/kg RGFP966 either 1 h before (pretraining) or immediately after (posttraining) subthreshold OLM training (Fig. S2C) showed enhanced preference for the object in a novel location during the retention test \([F(2,17) = 47.14, P < 0.001;\) Bonferroni post hoc vs. vehicle: 10 mg/kg RGFP966 pretraining, \(P < 0.05;\) 10 mg/kg RGFP966 pretraining, \(P < 0.05),\] with no effect on the total exploration time of objects [vehicle: 8.7 ± 2.3, \(n = 7;\) RGFP966 10 mg/kg pretraining: 8.0 ± 2.7, \(n = 6;\) RGFP966 10 mg/kg posttraining: 7.4 ± 1.9, \(n = 7;\) \(F(2,17) = 0.59, P = 0.56)](Fig. S2D). These results demonstrate that RGFP966 enhances acquisition/consolidation of memory.

**RGFP966 Facilitates Extinction and Prevents Reinstatement of Cocaine-Conditioned CPP Preference.** To examine the ability of RGFP966 to facilitate extinction of cocaine-conditioned place preference (CPP), we administered RGFP966 (3 or 10 mg/kg, s.c.) or vehicle immediately after posttest 1 and posttest 2 (Fig. 1A). All mice exhibited a robust preference for the cocaine-paired context after cocaine-CPP training [posttest 1; effect of test: \(F(1,13) = 135.8, P < 0.001;\) effect of treatment: \(F(2,26) = 1.016, P = 0.37)](Fig. 1B). Treatment with RGFP966 immediately after the drug-free preference tests resulted in significant extinction of CPP on posttest 2 and posttest 3 [effect of treatment × test, \(F(6,99) = 2.68, P < 0.05]).\] Treatment with 10 mg/kg, but not with 3 mg/kg, resulted in significantly rapid reduction of CPP on the subsequent days (posttest 2: Bonferroni post hoc, 10 mg/kg RGFP966 vs. vehicle, \(P < 0.05;\) 10 mg/kg RGFP966 vs. 3 mg/kg RGFP966, \(P < 0.05;\) posttest 3: 10 mg/kg RGFP966 vs. vehicle, \(P < 0.05;\) 10 mg/kg RGFP966 vs. 3 mg/kg RGFP966, \(P = 0.001;\) 3 mg/kg RGFP966 vs. vehicle, \(P > 0.05)\) for all test days). These results indicate that RGFP966 facilitates extinction of cocaine-seeking behavior.

To investigate the lasting effect of extinction, we subjected mice that had achieved an a priori extinction criterion by posttest 6 [one-sample t test, CPP score vs. 0: vehicle, 46.11 ± 54.85, \(t(10) = 0.84, P = 0.43;\) 3 mg/kg RGFP966, −38.36 ± 49.73, \(t(17) = 0.77, P = 0.47; 10 mg/kg RGFP966, 45.43 ± 40.74, t(17) = 1.11, P = 0.30;\) one-way ANOVA, \(F(2,20) = 1.03, P = 0.37]) to a reinstatement test. Mice previously treated with vehicle and 3 mg/kg RGFP966 significantly reestablished preference for the cocaine compartment [one-sample t test, CPP score vs. 0: vehicle, 270.2 ± 59.7, \(t(12) = 2.71, P < 0.05;\) 3 mg/kg RGFP966, 194.8 ± 39.03, \(t(17) = 4.99, P < 0.01)](Fig. 1C). However, mice previously treated with 10 mg/kg RGFP966 did not reestablish a preference [one-sample t test, CPP score vs. 0: −21.33 ± 53.54, \(t(17) = 0.40, P = 0.70;\) one-way ANOVA, \(F(2,20) = 5.29, P < 0.05;\) Bonferroni post hoc, vehicle vs. 3 mg/kg RGFP966, \(P = 0.03;\) vehicle vs. 10 mg/kg RGFP966, \(P = 0.03))$.
RGFP966, $P < 0.05$). These results indicate that treatment with 10 mg/kg RGFP966 immediately after extinction completely blocks reinstatement of cocaine-seeking behavior.

**Systemic RGFP966 Treatment After Cocaine-CPP Extinction Simultaneously Reduces Drug-Seeking Behavior and Enhances Long-Term Object Memory.** Given that the observed decrease in cocaine-CPP behavior after HDAC inhibitor treatment may be a result of either enhanced extinction or disrupted reconsolidation/performance, we developed a combined behavioral paradigm to assess memory enhancement versus impairment. By combining the extinction of cocaine-CPP and acquisition of OLM, we could assess the effect of a single injection of HDAC inhibitor on memory processes involved in extinction based on performance in both tasks simultaneously. After CPP training and OLM habituation (Fig. 2A), all mice exhibited robust CPP on posttest 1 [effect of test: $F_{(2,20)} = 21.65, P < 0.001$, Bonferroni post hoc: posttest 1 vs. pretest, $P < 0.05$] (Fig. 2B). Immediately after this nonreinforced exposure in the previously drug-paired context, mice received vehicle or 10 mg/kg RGFP966 and 1 h later were trained with subthreshold OLM (Fig. 2A), a time point at which RGFP966 is still present in brain (Fig. S1A). On posttest 2, mice treated with 10 mg/kg RGFP966 exhibited significantly reduced CPP for the previously cocaine-paired context compared with controls (Bonferroni post hoc: posttest 2, vehicle vs. RGFP966, $P < 0.05$) (Fig. 2B), replicating our findings shown in Fig. 1B. After posttest 2, the same RGFP966-treated mice showed significantly increased preference for the object in a novel location compared with controls [t test, $t_{(10)} = 4.15, P < 0.01$] (Fig. 2C), with no difference in total exploration time (vehicle: 12.68 ± 0.9527 s, $n = 6$; RGFP966: 12.56 ± 1.178 s, $n = 6$; $t = 0.08, P = 0.94$). In contrast, when RGFP966 was administered 8 h after training, there was no difference in cocaine-induced CPP or OLM compared with controls (CPP posttest 2: vehicle, $n = 7, 127.9 ± 22.87$ s, RGFP966 10 mg/kg, $n = 8, 127.8 ± 41.61$ s, $P = 0.05$; OLM: vehicle, $n = 7, −7.05 ± 1.5$ s, RGFP966 10 mg/kg, $n = 8, 4.6 ± 2.5$ s, $P = 0.05$). These findings indicate that the learning event (extinction or OLM) must be temporally contiguous with RGFP966 memory enhancement. Taken together, these results demonstrate that RGFP966 simultaneously enhances extinction consolidation of cocaine-CPP and acquisition of OLM.

To further examine the efficacy of RGFP966 in reducing drug-seeking behavior after extinction, we used a strong training paradigm (Fig. S3A) to establish robust CPP [posttest 1; vehicle: 246.1 ± 20.6 s, $n = 6$, one-sample $t$ test, $t_{(5)} = 11.94, P < 0.001$; RGFP966 10 mg/kg: 242.6 ± 16.1 s, $n = 6$, one-sample $t$ test, $t_{(5)} = 11.94, P < 0.001$] (Fig. S3B). Mice were treated with a single injection of RGFP966 (10 mg/kg) after posttest 1 and received subthreshold OLM training. When tested the next day for CPP and OLM, mice previously treated with RGFP966 no longer showed a significant preference for the cocaine-paired compartment by posttest 3, whereas vehicle-treated mice continued to show robust cocaine-CPP [significant effect of test: $F_{(3,30)} = 14.11, P < 0.001$, Bonferroni post hoc: vehicle, pretest vs. posttest 3, $P < 0.05$; RGFP966, pretest vs. posttest 3, $P = 0.05$] (Fig. S3B), and mice treated with RGFP966 also showed significantly increased preference for the object in a novel location compared with controls [unpaired $t$ test, $t_{(10)} = 7.47, P < 0.001$], with no difference in total exploration time [vehicle: 9.1 ± 2.1 s, $n = 6$; RGFP966: 8.0 ± 1.5 s, $n = 6$, $t_{(10)} = 0.44, P = 0.67$] (Fig. S3C). These results demonstrate that inhibition of HDAC3 can facilitate extinction of robust CPP behavior.

**RGFP966 Treatment Promotes Acetylation of Specific Histone Residues After Extinction.** The enhanced extinction of cocaine-CPP resulting from inhibition of HDAC3 during extinction consolidation led us to investigate how RGFP966 affects histone acetylation. We
examined the infralimbic cortex (IFC), hippocampus (HIPP), and nucleus accumbens (NAc) at 1 h after the first extinction session with vehicle or 10 mg/kg RGFP966 posttreatment. We first examined the acetylation of lysine 8 on H4 (H4K8Ac), a site regulated by HDAC3 activity in the brain (13), and found it was significantly increased in the IFC, but not in the HIPP or NAc, of the RGFP966-treated mice [one-sample t test: IFC, \( t(8) = 2.85, P < 0.05 \); HIPP, \( t(4) = 0.19, P = 0.86 \); NAc, \( t(4) = 1.14, P = 0.32 \)] (Fig. 3A). We then examined the acetylation of lysine 14 on histone H3 (H3K14Ac), which has been shown to correlate with learning (8, 12, 33, 34). We found a significant increase in H3K14Ac within the IFC, HIPP, and NAc in response to RGFP966 treatment [one-sample t test: IFC, \( t(8) = 2.74, P < 0.05 \); HIPP, \( t(8) = 2.49, P < 0.05 \); NAc, \( t(9) = 4.65, P < 0.01 \)] (Fig. 3B). We also found that RGFP966 did not alter the acetylation of lysine 12 on histone H2B [H2BK12Ac; one-sample t test: IFC, \( t(9) = 0.97, P = 0.35 \); HIPP, \( t(9) = 1.11, P = 0.30 \); NAc, \( t(9) = 0.69, P = 0.51 \)] (Fig. 3C).

**HDAC3 Regulates Gene Expression During Extinction Consolidation.** Acetylation of histones is a key mechanism in transcriptional regulation (4, 37). We predicted that the inhibition of HDAC3 and the resulting increase in histone acetylation would regulate the expression of key genes required for long-term changes in behavior. We examined c-fos and Nr4a2 because these immediate early genes (IEGs) are known to be regulated by HDAC3 in the brain (13). We examined c-fos expression during the consolidation
of extinction, at 1 h after extinction training. We found that HDAC3 inhibition promotes expression of the IEG c-fos in the IFC, but not in the HIP or NAc, during extinction consolidation [one-sample t test: IFC, t(13) = 5.08, P < 0.01; HIP, t(9) = 0.60, P = 0.70; NAc, t(9) = 0.43, P = 0.68] (Fig. 3D).

We next examined expression of the IEG and transcription factor Nr4a2 during extinction consolidation, which is known to play a key role in initial memory consolidation (38, 39). We found that mice treated with RGFP966 postextinction had increased Nr4a2 expression in the HIP, but not in the IFC or NAc [one-sample t test: IFC, t(9) = 0.95, P = 0.37; HIP, t(9) = 2.80, P < 0.05; NAc, t(9) = 0.28, P = 0.78] (Fig. 3E). Taken together, these results demonstrate that systemic treatment with RGFP966 promotes gene expression during extinction consolidation in brain regions implicated in extinction.

Finally, we examined the interaction of HDAC3 at the c-fos promoter in the IFC during extinction consolidation. ChiP analysis showed that RGFP966 significantly decreases HDAC3 occupancy at the c-fos promoter [one-sample t test: t(13) = 3.39, P < 0.01] (Fig. 3F) and promotes acetylation of histone H4K8 [one-sample t test: t(12) = 2.14, P < 0.05] during extinction consolidation (Fig. 3G). These findings indicate that RGFP966 alters the regulation of c-fos via HDAC3 and its acetylation during the consolidation of extinction.

Discussion

Enhancing the extinction of drug-seeking behavior via HDAC inhibition has tremendous therapeutic potential. Whether the rapid and persistent extinction of behavior results from the enhancement of memory processes involved in extinction is unclear, however. In the present study, we validate HDAC3 as a negative regulator of initial memory formation for ORM, and extend this to extinction consolidation of drug-seeking behavior. Our findings demonstrate that HDAC3 inhibition facilitates extinction by enhancing memory processes during consolidation of extinction. HDAC3 inhibition during acquisition or consolidation of a subthreshold ORM learning event resulted in robust long-term memory. Treatment with the HDAC3 inhibitor resulted in rapid and persistent extinction of cocaine-CPP. Using an innovative combination of behavioral paradigms, we have demonstrated that a single treatment with RGFP966 enhances the consolidation of extinction of a previously established cocaine-CPP, while enhancing ORM. Moreover, HDAC3 inhibition promotes the histone acetylation and gene expression necessary for memory formation during extinction consolidation. Thus, the observed blocked reinstatement of drug-seeking behavior cannot be explained simply by performance issues. Our results demonstrate that HDAC3 inhibition enhances memory processes involved in extinction of drug-seeking behavior.

Numerous previous studies have identified HDACs as powerful negative regulators of long-term potentiation and long-term memory (5, 7–9, 14, 15, 40–43). A recent analysis demonstrated that the HDAC inhibitors used in long-term memory studies (e.g., sodium butyrate, valproate) are potent inhibitors of class I HDACs (28). This suggests that class I HDACs (e.g., HDAC2 and HDAC3, but not HDAC1 [7, 13, 17]) play a significant role in the pharmacologic enhancement of memory. HDAC1 appears to have a permissive role in extinction of fear-related memories, but no role in initial memory formation (17). HDAC3 is the most highly expressed class I HDAC in the brain (29). In the present study, we found that the HDAC3 inhibitor RGFP966 transforms a subthreshold learning event into a robust long-term memory and facilitates the extinction of cocaine-seeking behavior in a persistent form that is refractive to reinstatement, indicating that HDAC3 normally has a repressive role in extinction processes.

The removal of acetylation by HDAC3 represses transcription by increasing the affinity of histone tails for DNA and recruiting complementary enzymes (e.g., methyltransferases, phosphatases) that further modify chromatin, reducing accessibility to DNA. Low levels of acetylation reduce the recruitment of transcriptional coactivators that typically bind acetyl-lysine motifs (44). Notably, HDAC3 can deacetylate, and thus inhibit the function of, the acetyltransferase CBP (45), which was recently shown to be necessary for the acquisition of cocaine-CPP (11). In a complex with corepressors, HDAC3 can interact with transcription factors, keeping their target genes in an inactive state (46, 47). Based on these findings, HDAC3 can be predicted to negatively regulate long-term memory. However, its role in extinction processes is not as predictable, in light of findings demonstrating that specific HDACs can play unique roles in memory processes (7, 13, 17), highlighting the significance of our present findings.

In this study, we found that inhibition of HDAC3 results in reduced interaction with the c-fos promoter, leading to increased levels of histone acetylation, which promotes the gene expression necessary for extinction processes in the IFC.

In a previous study using a genetic and pharmacologic approach, we found that HDAC3 is a critical negative regulator of long-term memory formation (13). Focal deletion of HDAC3 in the dorsal CA1 region of the HIP resulted in increased histone acetylation, gene expression, and long-term memory (13). HDAC3-dependent modulation of memory was found to be dependent on the transcription factor Nr4A2 (13). Using a selective HDAC3 inhibitor called RGFP136, we demonstrated parallel effects on histone acetylation and long-term memory formation to the genetic deletion of HDAC3 (13). In the present study, we could not use a focal deletion of HDAC3, because this could have effects on acquisition/consolidation of CPP that would confound the interpretation of extinction data. Thus, we only examined the effect of the HDAC3 inhibitor RGFP966 on extinction. RGFP966 is a more selective inhibitor than RGFP136 with a longer elimination half-life, significantly improved exposure, and better blood-brain barrier penetrance (with s.c. dosing producing a fourfold increase in overall brain exposure at the time when maximum brain concentration was reached for RGFP966 compared with RGFP136, with an improved brain: plasma ratio of 0.5 for RGFP966 vs. 0.2 for RGFP136 in mice), which makes it a more attractive compound for therapeutic use.

An alternative explanation for the absence of drug-seeking behavior after HDAC inhibition may be disrupted reconsolidation (e.g., memory erasure) or performance. In the present study, we examined this possibility by combining the extinction of drug-seeking behavior with acquisition of a new memory. Because extinction is measured as a reduction in behavior and ORM is observed as increased exploratory behavior of novelty, we were able to assess the effects on memory and performance. We found that selective inhibition of HDAC3 simultaneously eliminates drug-seeking behavior and enhances memory of a separate learning event, demonstrating that HDAC inhibition does not simply impair performance. Moreover, the effect of HDAC3 inhibition on extinction of drug-seeking behavior was temporally restricted. Taken together, these behavioral findings support the idea that inhibition of HDAC3 enhances memory processes involved in extinction consolidation. The persistent effect of HDAC inhibition on the extinction of cocaine-seeking behavior is consistent with the idea that specific HDACs are negative regulators of memory processes (48). It is hypothesized that pharmacologic inhibition of these negative regulators sets up a permissive state for the transcription processes required for consolidation, generating robust long-lasting memories, including persistent extinction that is refractive to reinstatement. In line with this hypothesis, RGFP966 reduced HDAC3 repression of c-fos and Nr4a2 and allowed increased acetylation of H4K8 and H3K14, two sites implicated in memory processes, during extinction consolidation.

In summary, HDAC3 appears to be a key negative regulator of memory formation, including the extinction of established memories. In the case of maladaptive behaviors, such as drug-seeking behavior, HDAC3 inhibition during extinction learning or cognitive behavioral therapy in drug abuse clinics and research centers may be...
a powerful cotherapy. This approach also could be applied to other cognitive disorders, such as posttraumatic stress disorder or anxiety disorders, that could potentially benefit from more robust extinction memory. With regard to basic research, there are many open questions regarding mechanisms, including the exact nature of the corepressor complex, what genes are being coordinately regulated, and where this regulation is most important in terms of extinction of drug-seeking behavior. The present study has begun to elucidate a specific pattern of histone acetylation and gene expression within the IFC, HIPP, and NAc that correlates with enhanced extinction. Future studies will be pivotal to our understanding of the HDAC3-dependent mechanisms important in changing cell function and ultimately leading to stable changes in behavior.

Materials and Methods

Male C57BL/6J mice were given the HDAC3 inhibitor RGFP966 to assess the effect on ORM, OLM, and extinction of cocaine-induced CPP. In brief, mice were treated with RGFP966 or vehicle and trained on ORM or OLM with a subthreshold training period. For extinction of CPP, RGFP966 or vehicle was given immediately after the posttest 1 and posttest 2, and once all mice achieved a prior extinction criterion, they received a retest reinstatement test. The effect of RGFP966 was examined by combining the extinction of cocaine-CPP and acquisition of OLM, separated by 1 h, in the same mice. The distribution of RGFP966 in brain and plasma was determined in a substrate-dependent biochemical assay using recombinant human HDACs at 15, 30, 60, and 120 min after systemic treatment. Histone acetylation, gene expression, and ChIP were examined during the consolidation of extinction in conjunction with RGFP966 treatment, with a levels were held at 0.05. See SI Materials and Methods for more detailed information.

ACKNOWLEDGMENTS. This work was supported by National Institutes of Mental Health Grant R01 MH081004 (to M.A.W.), National Institute on Drug Abuse Grants R01 DA025922 and R21 DA031989 (to M.A.W.), National Research Service Award Predoctoral Fellowship F31DA29368 (to M.M.), T32 Institutional Training Grant NS045540 (to G.A.R.), and Postdoctoral Fellowship F32DA031520 (to G.A.R.).
Supporting Information

Malvaez et al. 10.1073/pnas.1213364110

SI Materials and Methods

Animals. Male C57BL/6j mice (8 wk old; Jackson Laboratory) had access to food and water ad libitum. All procedures were performed during the light portion of the 12-h light/dark cycle and conducted in accordance with National Institutes of Health guidelines for animal care and use and. The study was approved by the University of California Irvine’s Institutional Animal Care and Use Committee.

Drugs. All drugs were administered at a volume of 10.0 mL/kg. RGFP966 (Ripligen) was dissolved in DMSO and diluted in a vehicle of 30% (wt/vol) hydroxypropyl-ß-cyclodextrin and 100 mM sodium acetate (pH 5.4). The final DMSO concentration was 10% (vol/vol) for drug and vehicle. RGFP966 was administered s.c. Cocaine-HCl (Sigma-Aldrich; 20 mg/kg) was dissolved in 10% (vol/vol) for drug and vehicle. RGFP966 (10 mg/kg s.c) or vehicle either immediately after posttest 1 or (as a negative control) 8 h after OLM training. The next day, CPP was assessed (posttest 2), and 1 h later an OLM retention test was performed.

Extinction of Cocaine-CPP Followed by OLM. Mice were conditioned with cocaine and tested as described above. Each day for 5 consecutive d, at 1 h after pretest and conditioning, mice were habituated to the OLM apparatus. CPP was assessed with the mice in a drug-free state (posttest 1), and 1 h later the mice were trained on OLM for 3 min. The mice received an injection of RGFP966 (10 mg/kg) or vehicle either immediately after posttest 1 or (as a negative control) 8 h after OLM training. The next day, CPP was assessed (posttest 2), and 1 h later an OLM retention test was performed.

Tissue Preparation. At 1 h after the first extinction session, mice were euthanized by cervical dislocation and brains were flash-frozen. Coronal sections and tissue punches from the infralimbic cortex (IFC), nucleus accumbens (NAc), and dorsal hippocampus (HIPP) were collected for immunofluorescence and ChIP analyses as described previously (5, 7–8).

Immunofluorescence. Slides were fixed in 4% paraformaldehyde for 10 min at room temperature, blocked in 8% normal goat serum (Jackson ImmunoResearch Laboratories) with 0.3% Triton X-100 in PBS, and incubated overnight at 4 °C with primary antibody in block solution, followed by a 2-h incubation at room temperature with secondary antibody. Primary antibodies used were acetyl-histone-H4K8 (1:2,000 dilution; Cell Signaling), acetyl-histone-H3K14 (1:1,000; Millipore), and acetyl-histone-H2BK12 (1:1,000; Abcam). The secondary antibody was goat anti-rabbit IgG-FITC (1:1,000; Chemicon). Immunolabeling was quantified by measuring the optical density in the area corresponding to the IFC [anterior–posterior (AP), +1.8 mm to +1.4 mm], dorsal HIPP (area CA1; AP, –1.5 mm to –2.0 mm), or NAc (including core and shell; AP, +1.3 mm to +1.0 mm) from comparable 20× images using ImageJ software.

Quantitative RT-PCR. Quantitative RT-PCR was performed to examine c-fos and Nr4a2 expression as reported previously (3–4, 9). Tissue was collected from IFC punches of IFC, NAc (core and shell), and dorsal HIPP (including CA1, CA2, CA3, and DG). Total RNA (75 ng) was reverse-transcribed and analyzed using the Roche proprietary algorithms and REST 2009 software based on the Pfaffl method (10–11). All values were normalized to GAPDH expression levels. Primers were derived from the Roche Universal Probe Library: c-Fos left primer, 5′-ggggcagttgaggagcagc-3′; c-Fos right primer, 5′-agctctcgctcttcag-3′; probe, atggtcgc; Nr4a2 left primer, 5′-tggctgctgggttatata-3′; Nr4a2 right primer, 5′-gggctgacctgctgtc-3′; probe, ttcctc (c-Fos and Nr4a2 probes are conjugated to the dye FAM); glyceraldehyde-3-phosphate dehydrogenase (GAPDH) left primer, 5′-atgtggaggtgtggta-3′; right primer, 5′-aactcccattgcaagct-3′; probe, tggccagtattg (GAPDH probe is conjugated to Lightcycler Yellow 555).

ChIP. Tissue was collected from mice at 1 h after the post-extinction injection of vehicle or RGFP966 (10 mg/kg). For each sample, bilateral IFC tissue was isolated from two 500-μm sections. ChIP was performed based on the protocol from Millipore
ChIP kit. In brief, tissue was cross-linked using 1% formaldehyde (Sigma-Aldrich), lysed, and sonicated, and chromatin was immunoprecipitated overnight with anti-HDAC3 (Millipore), anti-H4K8Ac (Millipore), or nonimmune rabbit IgG (negative control; Millipore). The immunoprecipitation was collected using magnetic Protein A beads (Millipore). After washing, chromatin was eluted from the beads and reverse cross-linked in the presence of proteinase K. DNA was purified and then quantified by quantitative PCR. c-fos promoter enrichment in ChIP samples was measured by quantitative PCR using a Roche Lightcycler 480 and SYBR Green. Primer sequences used to amplify the promoter region were designed by the Primer 3 program (c-Fos: 5'-tacgaccccttcaggcatac-3' and 5'-gttttaaaggacggcagcac-3'). A total of 5 μL of input, ChIP, or IgG sample was used in each reaction in duplicate, with eight biological samples for each condition. Percent input was calculated for both the ChIP and IgG samples, and fold enrichment was calculated as a ratio of the ChIP to IgG. An in-plate standard curve was used to determine amplification efficiency (AE) and the 100-fold dilution factor for the input was included. The equation used was AE[output cycle threshold (Ct)-ChIP Ct]×100/AE(input Ct-IgG Ct)×100. Samples were then normalized to the vehicle condition.

**Statistics.** Datasets were analyzed using the independent-samples t test, repeated-measures ANOVA, two-way ANOVA, or one-way ANOVA. Bonferroni post hoc tests were performed when appropriate. Simple planned comparisons were done using the Student t test, with α levels held at 0.05.


Fig. S1. Structure of RGFP966 and concentration in brain. (A) Chemical structure of the HDAC3 inhibitor RGFP966. International Union of Pure and Applied Chemistry name: (E)-N-(2-aminophenyl)-3-(1-cinnamyl-1H-pyrazol-4-yl)acrylamide. (B) Systemic administration of RGFP966 (10 mg/kg) enters the brain within 15 min. Peak concentration is reached at 30 min, is maintained through 60 min, and begins to decline by 120 min.
**Fig. S2.** HDAC3 inhibition enhances ORM. (A) Schematic of subthreshold novel ORM training, with immediate posttraining treatment and testing. (B) RGFP966 delivered immediately after training enhances ORM. Vehicle, n = 6; RGFP966 3 mg/kg, n = 5; RGFP966 10 mg/kg, n = 9; RGFP966 30 mg/kg, n = 5. (C) Schematic of subthreshold OLM training, with 1 h pretraining or immediate posttraining treatment, and testing. (D) RGFP966 pretraining or posttraining enhances OLM. Vehicle pretraining/posttraining, n = 7; RGFP966 10 mg/kg posttraining, n = 6; RGFP966 10 mg/kg pretraining, n = 7. Data are expressed as mean ± SEM. *Significantly different from vehicle; P < 0.05.

**Fig. S3.** HDAC3 inhibition facilitates the rate and persistence of extinction after robust cocaine-CPP training. (A) Schematic of extended cocaine-CPP training and extinction, followed in parallel by OLM training. RGFP966 is administered immediately after extinction training, 1 h before OLM training in the same mice; vehicle, n = 6; RGFP966 10 mg/kg, n = 6. (B) RGFP966 (10 mg/kg) immediately after a nonreinforced exposure results in loss of CPP by posttest 3. (C) RGFP966 treatment results in significantly enhanced object location memory. Data are expressed as mean ± SEM. †Significantly different from pretest; *significantly different from vehicle; P < 0.05.